Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

ECO 2021 May 10 - 13

Safety and Tolerability of Concomitant Administration of Multiple-Dose AM833 with Semaglutide 2.4 mg for Weight Management

Lone B Enebo1; Kasper K Berthelsen1; Martin Kankam2; Michael T Lund1; Domenica Rubino3; Altynai Satylganova1; David C W Lau4;
1Novo Nordisk A/S, Søborg, Denmark; 2Altasciences Clinical Kansas Inc., Overland Park, KS, USA; 3Washington Center for Weight Management, Arlington, VA, USA; 4Julia McFarlane Diabetes Research Centre and Libin Cardiovascular Institute of Alberta, University of Calgary Cumming School of Medicine, Calgary, AB, Canada;